Table 4.
Variable, n (%) | Placebo (n=11) | Drug (n=11) | p Value |
---|---|---|---|
Immediate post-PCI APV, cm/s | 19 (9, 26) | 30 (20, 37) | 0.030* |
Immediate post-PCI DSVR | 1.7 (1.3, 3.5) | 2 (1.4, 3.2) | 0.93 |
CBF immediately after PCI, mL/min | 53 (31, 94) | 80 (43, 119) | 0.19 |
CVR immediately after PCI, mm Hg/mL | 2.1 (1, 2.6) | 1.0 (0.8, 1.7) | 0.15 |
Adenosine APV, cm/s | 46 (34, 64) | 56 (48, 72) | 0.090 |
Adenosine DSVR | 1.9±0.9 | 1.6±0.5 | 0.24 |
Post-adenosine CBF, mL/min | 120 (84, 242) | 127 (104, 313) | 0.55 |
Post-adenosine CVR, mm Hg/mL | 0.65 (0.38, 1.55) | 0.59 (0.35, 0.8) | 0.50 |
Max CFR | 2.5 (1.8, 3) | 2.1 (1.6, 2.9) | 0.39 |
*p<0.05.
Data are expressed as median (IQR) or mean±SD.
APV, average peak velocity; CBF, coronary blood flow; CFR, coronary flow reserve; CVR, coronary vascular resistance; DSVR, diastolic/systolic velocity ratio.